Skip to main content

Table 1 Baseline Parameters

From: A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults

  100 mg IVIb (n = 31) 200 mg IVIb (n = 30) 400 mg IVIb (n = 31) Placebo
(n = 28)
Total
(n = 120)
N: Critically Ill 14 (45%) 12 (40%) 14 (45%) 13 (46%) 53 (44%)
N: Non-Critically Ill 17 (55%) 18 (60%) 17 (55%) 15 (54%) 67 (56%)
In ICU at BL 17 (55%) 15 (50%) 17 (55%) 16 (57%) 65 (54%)
On Mechanical Ventilation at BL 14 (45%) 12 (40%) 14 (45%) 13 (46%) 53 (44%)
On Presssor Support at BL 2 (7%) 2 (7%) 0 (0%) 0 (0%) 4 (3%)
Age (yrs) 40.1
(± 19.0 SD)
34.5
(± 15.0 SD)
39.2
(± 17.2 SD)
37.0
(± 19.1 SD)
37.8
(± 17.5 SD)
Gender 23 M, 8 F 22 M, 8 F 22 M, 9 F 21 M, 7 F 88 M, 32 F
Race Asian 10;
Black 5;
Caucasian 13;
Hispanic: 2;
Haitian 1.
Asian 10;
Black 4;
Caucasian 15;
Hispanic 1;
Haitian 0.
Asian 10;
Black 1;
Caucasian 16;
Hispanic 4;
Haitian 0.
Asian 10;
Black 3;
Caucasian 14;
Hispanic: 1;
Haitian 0.
Asian 40;
Black 13;
Caucasian 58;
Hispanic 8;
Haitian 1.
Temperature (/°C) 39.07 ± 0.61 39.07 ± 0.71 39.16 ± 0.72 38.89 ± 0.48 N/A
Highest Temp Prior to BL (°C) 39.4 ± 0.7 SD 39.4 ± 0.6 39.4 ± 0.7 39.2 ± 0.8 39.4 ± 0.7
Heart Rate (bpm) 106.0 ± 20.4 105.4 ± 18.4 102.7 ± 18.4 102.9 ± 15.4 104.3 ± 18.1
Mean Arterial Pressure 81.7 ± 12.9 83.3 ± 11.7 87.8 ± 12.7 88.1 ± 15.6 85.2 ± 13.4
Height
(cm)
170.3 ± 10.3 170.1 ± 10.5 168.2 ± 10.1 168.8 ± 11.8 169.4 (±10.6 SD)
Weight
(kg)
77.9 ± 32.6 80.3 ± 29.2 72.5 ± 23.4 78.4 ± 26.6 77.2 (± 28.0)
Positive Blood Culture 13 (42%)
(8 ± Malaria)
13 (43%)
(10 ± Malaria)
12 (39%)
9 ± Malaria
13 (46%)
10 ± Malaria
51 (43%)
37 ± Malaria
Modified APACHE II 11.4
(± 7.6 SD)
12.0
(± 7.7 SD)
13.4
(± 7.8 SD)
12.5
(± 9.7 SD)
12.3
(± 8.1 SD)
Glasgow Coma Score 3 to 8: 4 (13%)
9 to 12: 3 (10%)
>13:24 (77%)
3 to 8: 6 (20%)
9 to 12: 3 (10%)
>13:21 (70%)
3 to 8: 7 (23%)
9 to 12: 4 (13%)
>13:20 (65%)
3 to 8: 5 (18%)
9 to 12: 3 (11%)
>13:20 (71%)
3 to 8: 22 (18%)
9 to 12: 13 (11%)
>13:85 (71%)
Emerg. PostOp
Elect Post Op
Non Operative
2 (6%)
0 (0%)
29 (94%)
4 (13%)
0 (%)
26 (87%)
2 (6%)
3 (10%)
26 (84%)
1 (4%)
0 (0%)
27 (96%)
9 (%)
3 (%)
108 (%)
Chronic Conditions
(from Modified APACHE II)
Liver 0(0%)
CV 0 (0%)
Resp 1(3%)
Renal 0(0%)
Immun 2(6%)
None 28(90%)
Liver 0(0%)
CV 0 (0%)
Resp 1(3%)
Renal 0 (0%)
Immun 2(7%)
None 27(90%)
Liver 0 (0%)
CV 0 (0%)
Resp 1(3%)
Renal 0 (0%)
Immun1(3%)
None 29 (94%)
Liver 0 (0%)
CV 0 (0%)
Resp 1 (4%)
Renal 0 (0%)
Immun (7%)
None 25 (9%)
Liver 0 0%)
CV 0 (0%)
Resp 4(3%)
Renal 0 (0%)
Immun 7(6%)
None109 (91%)
WBC 11.6 ± 7.2 10.9 ± 6.6 9.6 ± 5.0 11.6 ± 6.4 10.9 ± 6.3
Creatinine (mg/dL) 0.95 ± 0.26 .97 ± 0.25 0.97 ± 0.35 1.0 ± 0.44 0.97 (±0.33)
Hematocrit
(%)
36.8 ± 7.7 34.1 ± 6.5 33.7 ± 6.0 34.5 ± 6.9 34.8 ± 6.8
Hemoglobin (g/dL) 12.3 ± 2.5 11.4 ± 2.2 11.4 ± 2.1 11.6 ± 2.3 11.7 ± 2.3
Platelet Count 221.6
(± 158.7)
189.7
(± 111.3)
173.6
(±116.3)
220.0
(±123.61)
200.9
(± 129.1)
Probable Site Infection None 1(3%);
Blood 9 (29%);
Lung 9 (29%);
Abdom 2 (6%)
Other 3 (10%)
CNS 2 (6%)
Urine Tr 0 (0%)
Skin/Tis 2 (6%)
Up Resp 2(6%)
GYN 0 (0%)
IV 1(3%)
Unk 2(6%)
None (3%)
Blood 10 (33%)
Lung 7 (23%)
Abdom 4 (13%)
Other 3 (10%)
CNS 3 (10%)
Urine Tr 0(0%)
Skin/Tis1 (3%)
Up Resp 0(0%)
GYN 0 (0%)
IV 0 (0%)
Unk 1 (3%)
None 2 (6%)
Blood 10 (32%)
Lung 9 (29%)
Abdom 1 (3%)
Other 4 (13%)
CNS 1 (3%)
Urine Tr 3 (10%)
Skin/Tis 0 (0%)
Up Resp1 (3%)
GYN 0(0%)
IV 0(0%)
Unk 0(0%)
None 2 (7%)
Blood 11 (39%)
Lung 5 (18%)
Abdom 4 (14%)
Other 1 (4%)
CNS 0 (0%)
Urine Tr 2 (7%)
Skin/Tis1(4%)
Up Resp 0 (0%)
GYN 1 (4%)
IV 0(0%)
Unk 1(4%)
None 6(5%)
Blood 40 (33%)
Lung 30 (25%)
Abdom 11 (9%)
Other 11 (9%)
CNS 6(5%)
Urine Tr 5 (4%)
Skin/Tis 4 (3%)
Up Resp 3 (3%)
GYN (1%)
IV 1(1%)
Unk 2(2%)
  1. BL, Baseline.